- Home
- BKSY vs ACRS Comparison
BKSY vs ACRS Comparison
Compare BKSY & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKSY | ACRS |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.0M | 868.5M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BKSY | ACRS |
|---|---|---|
| Price | $20.86 | $3.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $38.42 | $10.18 |
| AVG Volume (30 Days) | 826.6K | ★ 3.6M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.72 | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | $32.92 | N/A |
| Revenue Next Year | $36.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.41 | $1.74 |
| 52 Week High | $52.88 | $6.60 |
Technical Indicators
Market Signals| Indicator | BKSY | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 29.95 |
| Support Level | $20.40 | $3.16 |
| Resistance Level | $24.34 | $3.72 |
| Average True Range (ATR) | 1.21 | 0.40 |
| MACD | 0.01 | -0.18 |
| Stochastic Oscillator | 10.61 | 20.49 |
Price Performance
Historical ComparisonAbout BKSY BlackSky Technology Inc.
BlackSky Technology Inc is a space-based technology company that delivers real-time imagery, analytics and high-frequency monitoring of the worlds critical and strategic locations, economic assets, and events. By taking a software-first technology approach, Company is delivering real-time space-based intelligence at disruptive speed, scale and economics. Companies single operating and reportable segment, provided space-based intelligence products and services through three integrated revenue streams-space-based intelligence & AI services, mission solutions, and technology programs. Geographically, the company operates in United States and Rest of world.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.